Volume | 5,526,101 |
|
|||||
News | - | ||||||
Day High | 1.68 | Low High |
|||||
Day Low | 1.52 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Perspective Therapeutics Inc | CATX | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.53 | 1.52 | 1.68 | 1.60 | 1.53 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16,515 | 5,526,101 | $ 1.62 | $ 8,934,139 | - | 0.205 - 1.905 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:13:47 | 1 | $ 1.5708 | USD |
Perspective Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
106.62M | 280.57M | - | 1.43M | -46.51M | -0.17 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Perspective Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CATX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.80 | 1.905 | 1.32 | 1.63 | 9,043,986 | -0.20 | -11.11% |
1 Month | 1.44 | 1.905 | 1.32 | 1.67 | 5,844,239 | 0.16 | 11.11% |
3 Months | 0.94 | 1.905 | 0.851 | 1.44 | 4,996,828 | 0.66 | 70.21% |
6 Months | 0.254 | 1.905 | 0.228 | 1.23 | 3,263,492 | 1.35 | 529.92% |
1 Year | 0.50 | 1.905 | 0.205 | 1.08 | 1,936,973 | 1.10 | 220.00% |
3 Years | 0.3763 | 1.905 | 0.205 | 1.04 | 1,700,519 | 1.22 | 325.19% |
5 Years | 0.3763 | 1.905 | 0.205 | 1.04 | 1,700,519 | 1.22 | 325.19% |
Perspective Therapeutics Description
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Company¿s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions. |